Results 51 to 60 of about 90,099 (312)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Optimized type-2 fuzzy controller based on IoMT for stabilizing the glucose level in type-1 diabetic patients

Scientific Reports, 2023
Due to advancements in existing Internet of Medical Things (IoMT) systems and devices, the blood glucose level (BGL) for type-1 diabetic patients (T1DPs) is effectively and continually monitored and controlled by Artificial Pancreas.
Amged Sayed, Belal A. Zalam, Mohanad Elhoushy, Essam Nabil   +3 more
doaj   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Conventional insulin pump therapy in two neonatal diabetes patients harboring the homozygous PTF1A enhancer mutation: Need for a novel approach for the management of neonatal diabetes

The Turkish Journal of Pediatrics, 2017
The enhancer of PTF1A mutation causes developmental defects of the pancreas. This condition can result in insulin-requiring diabetes and exocrine pancreatic insufficiency.
Erdal Kurnaz, Zehra Aycan, Nurdan Yıldırım, Semra Çetinkaya   +3 more
doaj   +1 more source

Picoliter-volume inkjet printing into planar microdevice reservoirs for low-waste, high-capacity drug loading. [PDF]

, 2017
Oral delivery of therapeutics is the preferred route for systemic drug administration due to ease of access and improved patient compliance. However, many therapeutics suffer from low oral bioavailability due to low pH and enzymatic conditions, poor ...
Bogdanoff, Derek B, Cantlon, Joshua, Chevalier, Rachel W, Desai, Tejal A, Fox, Cade B, Hsiao, Jeff C, Nemeth, Cameron L   +6 more
core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

Insulin delivery devices in diabetes management: Applications and advancements

Intelligent Pharmacy
With continuous advancements in diabetes management technology, insulin delivery devices have become increasingly central to the treatment of diabetes.
Runhuang Yang, Zongwen Yang, Jingnan Chi, Ya Zhu   +3 more
doaj   +1 more source

Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care

Frontiers in Pharmacology, 2022
There are a number of ongoing developments to improve the care of patients with diabetes across countries given its growing burden. Recent developments include new oral medicines to reduce cardiovascular events and death.
Ileana Mardare, Stephen M. Campbell, Johanna C. Meyer, Israel Abebrese Sefah, Amos Massele, Brian Godman, Brian Godman, Brian Godman   +7 more
doaj   +1 more source

Effects of pre-exercise carbohydrate consumption on metabolism during exercise [PDF]

, 2016
It is well documented that consuming carbohydrates (CHO) prior to exercise has been shown to alter metabolism. There are many ways that CHO ingestion affects substrate utilization and blood glucose dynamics at the start of exercise.
Montzingo, Luke James
core   +1 more source